Cascadian Therapeutics Announces Poster Presentations on

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cascadian Therapeutics Announces Poster Presentations on Tucatinib at the European Society of Medical Oncology (ESMO) 2016 Congress

SEATTLE, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ: CASC ), a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations on tucatinib (ONT-380), the Company’s lead product candidate for the treatment of HER2+ breast cancer, at the European Society of Medical Oncology (ESMO) 2016 Congress being held October 7 -11, 2016 in Copenhagen, Denmark.

Details of Poster Presentations:

Title: Cutaneous responses in Her-2+ metastatic breast cancer (MBC) on phase 1b study of ONT-380, an oral HER2-specific inhibitor in combination with capecitabine (C) and/or trastuzumab (T) in third line or later treatment Poster Number: 278 Date: Monday, October 10, 2016 Time: 1:00pm – 2:00pm (CEST)

Title: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) Poster Number: 312 (trial in progress) Date: Monday, October 10, 2016 Time: 1:00pm – 2:00pm (CEST)

About Cascadian Therapeutics Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Our lead product candidate, tucatinib, also known as ONT-380, is an orally active and selective small molecule HER2 inhibitor, which has been studied in approximately 200 patients to date. Preliminary results from two ongoing Phase 1b studies of tucatinib in combination showed promising systemic activity, a favorable safety profile and encouraging activity against brain metastases. Cascadian Therapeutics is also conducting a randomized, double-blind, placebo-controlled Phase 2 study called  HER2CLIMB . The study is evaluating tucatinib versus placebo in combination with capecitabine and trastuzumab in late stage HER2+ breast cancer patients, with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. This study is expected to enroll 180 patients across approximately 100 clinical sites in the U.S., Canada, and Western Europe. The Company is also developing a cell cycle inhibitor, Chk1, and plans to move the program forward through IND-enabling studies in 2017. For more information, visit  www.cascadianrx.com .

Investor Contact: Julie Rathbun Rathbun Communications 206-769-9219 ir@cascadianrx.com Naomi Eichenbaum The Trout Group 646-378-2968 neichenbaum@troutgroup.com Media Contact: Susie Myers BMC Communications 646-513-3116 smyers@bmccommunications.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

OmniActive's Fenavari: A New Era in Women's Health

Updated Category News Views 42

Pioneering Women's Health with Fenavari You ever wonder why some health products get all the hype? Here's one for the book: OmniActive Health Technologies launching Fenavari, their top-tier contender in the women's health market. Now, we're not talking your run-of-the-mill supplement here. We're stepping onto a new playing field, especially with Dr. Taz Bhatia stepping...

Continue Reading
Skiptown Expands in Georgia Amid Growing Demand

Updated Category News Views 30

With the pet care industry barking up a storm lately, Skiptown is ramping up efforts to expand its presence in Georgia. The tech-enabled dog care franchise already has a paw print in Atlanta, but it's sniffing out new opportunities across the state. Now they're on the hunt for franchise owners who can bring this modern approach to more communities. Why Georgia? The Growth...

Continue Reading
Quark Baby's Milk Warmer Debut at Vancouver & Dubai

Updated Category News Views 29

An Unconventional Pitch for Baby Gear Quark Baby is strutting its stuff not just in Vancouver but all the way in Dubai. Yeah, we're talking about a milk warmer hitting two major expos. What's the deal with an award-winning brand from Vancouver making so much noise? From October 17-18, they're home-court at The Baby Show Vancouver, and by October 22-24, they're in Dubai at...

Continue Reading
New Data on SKYRIZI Offers Hope for Crohn's Patients

Updated Category News Views 30

Treating Crohn's: New Hope on the Horizon Folks, let me tell you, the landscape for treating Crohn's disease just got a bit more interesting. AbbVie's Phase 3 AFFIRM study has brought some attention-grabbing data on the table, showcasing the potential of their drug, SKYRIZI® (risankizumab-rzaa). This ain't just another run-of-the-mill study; these results could be a...

Continue Reading
VetsinTech's AI Training Boosts Military Careers

Updated Category News Views 44

A New Spin on Engineering Careers Sometimes it feels like every corner I turn in this market maze, there’s something about AI. It’s not just chirping in the tech world anymore; it’s banging on the doors of sectors like engineering, aerospace, and manufacturing. And now, VetsinTech is tossing its hat into the AI ring with a fresh program aimed at blending military...

Continue Reading
Fluence Energy Faces Major Lawsuit Amid $3B Loss

Updated Category News Views 17

Securities Class Action: A Storm Brewing Just when you think you've got a grip on the market, a sharp right hook can come out of nowhere. Fluence Energy (NASDAQ:FLNC) is dealing with one of those punches now, getting dragged into the courtroom over claims they fudged financial lines. They hail innovation in energy storage, but shareholders are left shaking in their boots...

Continue Reading
Dr. Anderson’s Journey: Leadership with Faith and Service

Updated Category News Views 8

A Life Shaped by Service Dr. Howard Anderson isn't just another name in a glossy award roster—he's a powerhouse of leadership, a chaplain of compassion, and a soldier in spirit. Honored as a Pinnacle Professional Member of The Inner Circle of Excellence, his recognition feels less like an accolade and more like a testament to a life committed to serving others. The...

Continue Reading
Paradigm Therapeutics: A Beacon in Rare Diseases

Updated Category News Views 4

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

Continue Reading
Think Tank Pushes for Bold Parkinson's Prevention Plan

Updated Category News Views 28

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

Continue Reading
Honeywell Aerospace Faces Legal Turbulence in Fraud Case

Updated Category News Views 13

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

Continue Reading

Top 5 Most Recently Viewed Articles

Ciena's Role in the Expanding AI Infrastructure Landscape

Updated Category News Views 205

Ciena's Pivotal Contribution to AI and Cloud Technology Ciena Co. (NYSE: CIEN) has established itself as a vital player in the technology sector, particularly within the realm of networking solutions. This company, which has a rich history dating back to 1992 as one of the original optical fiber manufacturers, has successfully adapted to the rapidly evolving landscape of...

Continue Reading
BranchOut Food Achieves Significant Growth in Q1 Revenue

Updated Category News Views 181

BranchOut Food Reports Record Q1 Revenue Key Highlights: Q1 Revenue of $3.2 Million, reflecting a notable 118% increase with optimistic growth anticipated throughout the year. Targeted to achieve debt-free status by the end of 2025. Peru Facility Fully Operational, capable of supporting over $40 million in annual production. Expanded Warehouse Club Partnership

Continue Reading
Investigation of CNB Bank Shares: Your Rights as a Shareholder

Updated Category News Views 230

Investigation of CNB Bank Shares Inc. Transactions Recently, the M&A Class Action Firm has launched an investigation regarding CNB Bank Shares, Inc. (OTCMKTS: CNBN) due to its proposed sale to HBT Financial, Inc. This inquiry seeks to determine if the deal being offered to shareholders is fair and just. When a company is involved in such significant transactions, it...

Continue Reading
Innovative Shoe Cleaning Device Revolutionizes Footwear Care

Updated Category News Views 318

Revolutionary Shoe Cleaning Innovation In a world where cleanliness is paramount, one inventor has taken a significant step forward by designing an innovative shoe cleaning device. This creation aims to enhance the cleanliness within homes, a vital aspect given the constant tracking of dirt and debris that often occurs when entering a home. The inventor, who...

Continue Reading
Breezeline Expands Fiber Internet Services Across Virginia

Updated Category News Views 133

Breezeline Expands Fiber Internet Services Across Virginia Breezeline, a prominent internet, TV, phone, and wireless service provider, is making strides in enhancing internet connectivity by launching a significant fiber-to-the-home (FTTH) initiative. This expansion aims to provide homes and businesses in eight Virginia communities with high-speed fiber internet, a...

Continue Reading